Regeneron other research news

REGN announced a broad drug discovery program to identify protein factors that bind to recently discovered receptors that are members of the tyrosine kinase family.

REGN has cloned more than a dozen such receptors in-house and has exclusively licensed eight more from The Salk Institute for Biological Studies. Under the license, REGN will develop and market products containing the receptor genes and the proteins they encode, as well as molecules discovered using the technology. ...